Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril valsartan vs valsartan in mid-range EF ventricular aneurysm after MI
ChiCTR2100041700Phase 4Recruiting
- Sponsor
- Xiamen Cardiovascular Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sacubitril + valsartan and valsartan in left ventricular aneurysm (LVA), myocardial infarction (MI) and heart failure with mid-range ejection fraction (HFmrEF) (2 arms), sponsored by Xiamen Cardiovascular Hospital. Primary endpoints: Cardiac ultrasound and Cardiac magnetic resonance. Started Jan 2021; status: recruiting.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
left ventricular aneurysm (LVA)myocardial infarction (MI)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on ChiCTR2100041700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041700.